Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.
about
A pilot study using next-generation sequencing in advanced cancers: feasibility and challengesThe Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of JanusFibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implicationsWhat a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathwayEarly phase clinical trials to identify optimal dosing and safetyPhase I trials of antitumour agents: fundamental conceptsFBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.A practical approach to aid physician interpretation of clinically actionable predictive biomarker results in a multi-platform tumor profiling serviceIntegrating next-generation sequencing into clinical oncology: strategies, promises and pitfallsThe possibility of clinical sequencing in the management of cancerThe National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare CancersProspective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trialsNF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers.Multi-marker Solid Tumor Panels Using Next-generation Sequencing to Direct Molecularly Targeted Therapies.Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigmsPilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.Characteristics and survival of patients with advanced cancer and p53 mutations.Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint HypothesisTarget-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancerTumour heterogeneity in the clinic.The AURORA initiative for metastatic breast cancer.Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agentsFool's gold, lost treasures, and the randomized clinical trial.Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experienceUnique molecular landscapes in cancer: implications for individualized, curated drug combinations.Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.Tumor genome analysis includes germline genome: are we ready for surprises?Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases.Application of molecular profiling in clinical trials for advanced metastatic cancers.Personal genomes, quantitative dynamic omics and personalized medicine
P2860
Q21132483-CD15283D-68E8-4392-A5F6-1E1D550930B1Q26740184-EAC6E801-31A2-4993-9C1D-47EFEE83EDE1Q26801718-450E413A-7075-47BD-85B8-211FDC2F32D2Q26825780-9BD60B46-C4DA-4195-80D1-25FC78186289Q26865076-1B3041A4-F4B8-4E14-BA00-1098710FE969Q26865346-D07BD0AF-ECDE-414A-8EE2-70F2CDE3C566Q27852932-A31347A2-8B1C-4CA3-B2EE-4E2CFFBDA591Q27853000-8B0DD0AA-0538-4C47-AF0D-EFAC3C7C0F46Q28066709-AAA8CC96-2475-42B5-9333-D9EB2BF19A6EQ28072144-6C5CED8B-29C8-49A5-A14D-F4616FC824D2Q28087174-E357AA61-0E6C-4CB8-BD19-6D76F66954AEQ28540955-9AFC19E6-2D40-4449-B7E2-EB0BC49893B1Q30440530-972EC79C-5506-4140-9C41-9B8E5B8D0321Q30826387-A33A2B64-67C2-4882-A617-4286CBF8EAB1Q33410022-C7682DF1-41A1-4B95-A371-87735386A813Q33429608-A223210D-6E65-45FC-A622-6921D3D0E2D3Q33685000-9B7B7486-0AAD-43DF-83A3-9431A130D290Q33686447-51B3EA1D-EEB1-4A53-955B-D7927C010D5EQ33688966-617A1FCC-A419-4608-9C52-890509AE6FA1Q33699594-2EF3152E-230A-46BE-B3F0-41984AE99235Q33756991-70CFFEB8-49EF-4BE4-AAA4-A092E702459DQ33858387-28C68A5E-B2BE-4A11-A261-4B348B592DBDQ33877385-9DE28688-DDB1-46B4-B9B0-D74A07C5B9ECQ33917551-09F28BC4-4984-4E13-9290-87BDA871EE52Q33977102-D9EE4BE5-024F-41F6-B1C6-D872A1C66F4FQ34025926-42756D7D-4914-42A4-BD66-E6DA37C6AD6EQ34153696-E279EF9A-4B61-4E60-8806-8582390B2912Q34295621-B318189A-E9F6-4378-A239-42774CF0B905Q34372080-7DF5922E-FF6A-4627-AFCA-A457C7225A7BQ34499602-275A9530-2594-440B-A0D4-D067B4AD922EQ34619163-C26888AE-7B02-4A70-8FC8-C28FCC572290Q34646376-5C5978C6-21E0-447E-A623-88177540C116Q34669260-3883BD06-2D1C-4F13-8FDC-F7DB167E3284Q34781347-A88AABA4-A765-4784-8A21-69B3F6384CC6Q34938532-7E78C540-09B0-41F2-ABC2-6532FAFC2333Q34957243-77393839-3308-4645-BFE6-3163FBF141D4Q35004182-CE7A0435-94FF-4903-8AA8-02BBD8EE172AQ35068021-FA70B3DC-8C8A-40DA-896D-18E36E65DF2AQ35102633-E4E760B5-5CE9-4C18-9D69-9750EB1F2FCAQ35195408-877EB304-F6D0-4ED3-988A-00417F7897E7
P2860
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Personalized medicine in a pha ...... rson Cancer Center initiative.
@ast
Personalized medicine in a pha ...... rson Cancer Center initiative.
@en
type
label
Personalized medicine in a pha ...... rson Cancer Center initiative.
@ast
Personalized medicine in a pha ...... rson Cancer Center initiative.
@en
prefLabel
Personalized medicine in a pha ...... rson Cancer Center initiative.
@ast
Personalized medicine in a pha ...... rson Cancer Center initiative.
@en
P2093
P2860
P50
P1476
Personalized medicine in a pha ...... rson Cancer Center initiative.
@en
P2093
David S Hong
Donald Berry
Gerald S Falchook
Jennifer J Wheler
Nancy G Iskander
Rajyalakshmi Luthra
Sarina Piha-Paul
P2860
P304
P356
10.1158/1078-0432.CCR-12-1627
P407
P577
2012-09-10T00:00:00Z